Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand
Overview
The purpose of this study is to evaluate health status of uncontrolled Chronic Obstructive Pulmonary Disease (COPD) patients in response to treatments in clinical practice.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: March 2012
Detailed Description
MC MD
Clinical Trial Outcome Measures
Primary Measures
- Changes in PEF and overall CCQ score
- Time Frame: between the first visit and after 12 (plus or minus 1) weeks
Secondary Measures
- Difference of the changes of PEF and overall CCQ score comparing between various treatments
- Time Frame: between the first visit and after 12 (plus or minus 1) weeks
Participating in This Clinical Trial
Inclusion Criteria
1. Provision of informed consent prior to any study specific procedures 2. Male or non-pregnant female aged >40 years 3. A clinical diagnosis of COPD with FEV1/ FVC <0.70 and require combination or modified therapy 4. Smoke > 10 Pack Year Exclusion Criteria:
1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) 2. Participation in a clinical study (precluding non-interventional study or registry) during the last 3 months
Gender Eligibility: All
Minimum Age: 41 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- AstraZeneca
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Assoc. Prof. Watchara Boonsawat, Principal Investigator, Khon Kaen University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.